25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ScinoPharm Taiwan Ltd
Buy, Hold or Sell?

Let's analyze Scinopharm together

I guess you are interested in ScinoPharm Taiwan Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of ScinoPharm Taiwan Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about ScinoPharm Taiwan Ltd

I send you an email if I find something interesting about ScinoPharm Taiwan Ltd.

1. Quick Overview

1.1. Quick analysis of Scinopharm (30 sec.)










1.2. What can you expect buying and holding a share of Scinopharm? (30 sec.)

How much money do you get?

How much money do you get?
NT$0.01
When do you have the money?
1 year
How often do you get paid?
72.5%

What is your share worth?

Current worth
NT$13.10
Expected worth in 1 year
NT$13.34
How sure are you?
75.0%

+ What do you gain per year?

Total Gains per Share
NT$0.60
Return On Investment
2.5%

For what price can you sell your share?

Current Price per Share
NT$24.20
Expected price per share
NT$23.50 - NT$26.50
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Scinopharm (5 min.)




Live pricePrice per Share (EOD)
NT$24.20
Intrinsic Value Per Share
NT$1.79 - NT$17.98
Total Value Per Share
NT$14.89 - NT$31.08

2.2. Growth of Scinopharm (5 min.)




Is Scinopharm growing?

Current yearPrevious yearGrowGrow %
How rich?$324.6m$324.5m$180.1k0.1%

How much money is Scinopharm making?

Current yearPrevious yearGrowGrow %
Making money$3.1m$2m$1.1m35.2%
Net Profit Margin11.1%8.2%--

How much money comes from the company's main activities?

2.3. Financial Health of Scinopharm (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Scinopharm?

Welcome investor! Scinopharm's management wants to use your money to grow the business. In return you get a share of Scinopharm.

First you should know what it really means to hold a share of Scinopharm. And how you can make/lose money.

Speculation

The Price per Share of Scinopharm is NT$24.20. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Scinopharm.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Scinopharm, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is NT$13.10. Based on the TTM, the Book Value Change Per Share is NT$0.06 per quarter. Based on the YOY, the Book Value Change Per Share is NT$0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is NT$0.09 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Scinopharm.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 NT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per Share
Usd Eps0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Book Value Change Per Share-0.010.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.010.0%0.010.0%
Usd Total Gains Per Share-0.010.0%0.000.0%0.000.0%0.010.0%0.010.0%
Usd Price Per Share0.91-0.87-0.83-0.85-1.08-
Price to Earnings Ratio76.65-81.54-81.33-140.85-168.44-
Price-to-Total Gains Ratio-138.91-61.40-408.44-82.97-28.52-
Price to Book Ratio2.21-2.11-2.03-2.09-2.72-
Price-to-Total Gains Ratio-138.91-61.40-408.44-82.97-28.52-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.75746
Number of shares1320
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.01
Gains per Quarter (1320 shares)6.1811.90
Gains per Year (1320 shares)24.7047.60
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
115101545338
230204090686
34530651358134
459399017911182
5744911522414230
6895914026917278
71046916531419326
81197919035922374
91348921540425422
101499824044828470

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%56.00.00.0100.0%
Book Value Change Per Share3.01.00.075.0%8.04.00.066.7%14.06.00.070.0%26.014.00.065.0%37.017.02.066.1%
Dividend per Share1.00.03.025.0%6.00.06.050.0%13.00.07.065.0%29.00.011.072.5%34.00.022.060.7%
Total Gains per Share3.01.00.075.0%8.04.00.066.7%14.06.00.070.0%30.010.00.075.0%41.013.02.073.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of ScinoPharm Taiwan Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.2090.060-451%0.024-987%0.017-1347%0.042-596%
Book Value Per Share--13.10113.1070%13.101+0%12.930+1%12.818+2%
Current Ratio--6.8628.194-16%7.540-9%7.975-14%5.817+18%
Debt To Asset Ratio--0.1350.122+11%0.127+7%0.122+11%0.158-14%
Debt To Equity Ratio--0.1570.139+13%0.146+8%0.139+12%0.189-17%
Dividend Per Share---0.090-100%0.120-100%0.271-100%0.309-100%
Eps--0.0950.127-26%0.087+9%0.092+3%0.122-23%
Free Cash Flow Per Share---0.0110.102-111%0.060-118%0.124-109%0.186-106%
Free Cash Flow To Equity Per Share---0.028-0.014-48%-0.045+65%-0.064+131%0.049-157%
Gross Profit Margin--0.3950.417-5%0.321+23%-0.040+110%0.107+270%
Intrinsic Value_10Y_max--17.977--------
Intrinsic Value_10Y_min--1.788--------
Intrinsic Value_1Y_max--0.897--------
Intrinsic Value_1Y_min--0.341--------
Intrinsic Value_3Y_max--3.384--------
Intrinsic Value_3Y_min--0.892--------
Intrinsic Value_5Y_max--6.702--------
Intrinsic Value_5Y_min--1.290--------
Market Cap19135883993.600-20%22958227000.00021898646312.800+5%21035334606.275+9%21740085819.298+6%27648956745.939-17%
Net Profit Margin--0.0980.111-11%0.082+20%0.091+8%0.110-11%
Operating Margin--0.0930.132-29%0.103-9%0.116-20%0.144-35%
Operating Ratio--0.9070.881+3%0.914-1%0.895+1%0.865+5%
Pb Ratio1.847-20%2.2132.111+5%2.030+9%2.090+6%2.724-19%
Pe Ratio63.961-20%76.64881.544-6%81.331-6%140.849-46%168.441-54%
Price Per Share24.200-20%29.00027.663+5%26.575+9%27.003+7%34.599-16%
Price To Free Cash Flow Ratio-564.075+17%-675.958-214.408-68%61.597-1197%34.371-2067%35.768-1990%
Price To Total Gains Ratio-115.920+17%-138.91361.397-326%408.442-134%82.974-267%28.521-587%
Quick Ratio--4.8345.922-18%5.838-17%6.073-20%4.282+13%
Return On Assets--0.0060.009-27%0.005+14%0.006+2%0.008-21%
Return On Equity--0.0070.010-25%0.006+15%0.007+3%0.010-24%
Total Gains Per Share---0.2090.149-240%0.144-245%0.288-172%0.351-159%
Usd Book Value--324642473.200324766546.4000%324586422.725+0%325740212.7150%321305035.580+1%
Usd Book Value Change Per Share---0.0070.002-451%0.001-987%0.001-1347%0.001-596%
Usd Book Value Per Share--0.4100.4100%0.410+0%0.405+1%0.401+2%
Usd Dividend Per Share---0.003-100%0.004-100%0.008-100%0.010-100%
Usd Eps--0.0030.004-26%0.003+9%0.003+3%0.004-23%
Usd Free Cash Flow---265768.3002522451.350-111%1477180.025-118%3121916.775-109%4650881.868-106%
Usd Free Cash Flow Per Share--0.0000.003-111%0.002-118%0.004-109%0.006-106%
Usd Free Cash Flow To Equity Per Share---0.0010.000-48%-0.001+65%-0.002+131%0.002-157%
Usd Market Cap598953169.000-20%718592505.100685427629.591+5%658405973.176+9%680464686.144+6%865412346.148-17%
Usd Price Per Share0.757-20%0.9080.866+5%0.832+9%0.845+7%1.083-16%
Usd Profit--2343806.6003153490.650-26%2043060.550+15%2287671.615+2%3038147.020-23%
Usd Revenue--23861836.70026826737.025-11%24444509.675-2%24170080.665-1%26380755.063-10%
Usd Total Gains Per Share---0.0070.005-240%0.004-245%0.009-172%0.011-159%
 EOD+4 -4MRQTTM+5 -31YOY+18 -185Y+16 -2010Y+12 -24

3.3 Fundamental Score

Let's check the fundamental score of ScinoPharm Taiwan Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1563.961
Price to Book Ratio (EOD)Between0-11.847
Net Profit Margin (MRQ)Greater than00.098
Operating Margin (MRQ)Greater than00.093
Quick Ratio (MRQ)Greater than14.834
Current Ratio (MRQ)Greater than16.862
Debt to Asset Ratio (MRQ)Less than10.135
Debt to Equity Ratio (MRQ)Less than10.157
Return on Equity (MRQ)Greater than0.150.007
Return on Assets (MRQ)Greater than0.050.006
Total6/10 (60.0%)

3.4 Technical Score

Let's check the technical score of ScinoPharm Taiwan Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose23.300
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About ScinoPharm Taiwan Ltd

ScinoPharm Taiwan, Ltd., together with its subsidiaries, research and develops, produces, and sells active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, rest of Asia, Europe, India, the United States and internationally. The company provides small molecular drugs, protein drugs, complex natural molecules and derivatives, synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; outsourcing services. It offers CRAM services, such as chemistry skill, analytical and regulatory, chemical process development, clinical drug substance, and consulting services for the development and manufacturing of clinical, small-scale, and commercial-stage APIs and intermediates, as well as develops peptide synthesis technologies. In addition, the company develops and manufactures western medicines and other chemical materials, albumin and oligonucleotide medicines, and injections. as well as provides biological technology services, technical, and Intellectual property rights related services. It has a strategic alliance with Baxter International Inc. to develop, manufacture, and commercialize of antiemetic drug in chemotherapy for cancer. The company was incorporated in 1997 and is headquartered in Tainan City, Taiwan.

Fundamental data was last updated by Penke on 2024-10-29 05:19:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Scinopharm earns for each NT$1 of revenue.

  • Above 10% is considered healthy but always compare Scinopharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 9.8% means that NT$0.10 for each NT$1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of ScinoPharm Taiwan Ltd:

  • The MRQ is 9.8%. The company is making a profit. +1
  • The TTM is 11.1%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ9.8%TTM11.1%-1.3%
TTM11.1%YOY8.2%+2.9%
TTM11.1%5Y9.1%+2.0%
5Y9.1%10Y11.0%-1.9%
4.3.1.2. Return on Assets

Shows how efficient Scinopharm is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Scinopharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.6% Return on Assets means that Scinopharm generated NT$0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of ScinoPharm Taiwan Ltd:

  • The MRQ is 0.6%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.9%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.6%TTM0.9%-0.2%
TTM0.9%YOY0.5%+0.3%
TTM0.9%5Y0.6%+0.2%
5Y0.6%10Y0.8%-0.2%
4.3.1.3. Return on Equity

Shows how efficient Scinopharm is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Scinopharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.7% Return on Equity means Scinopharm generated NT$0.01 for each NT$1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of ScinoPharm Taiwan Ltd:

  • The MRQ is 0.7%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.0%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.7%TTM1.0%-0.2%
TTM1.0%YOY0.6%+0.3%
TTM1.0%5Y0.7%+0.3%
5Y0.7%10Y1.0%-0.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of ScinoPharm Taiwan Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Scinopharm is operating .

  • Measures how much profit Scinopharm makes for each NT$1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Scinopharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 9.3% means the company generated NT$0.09  for each NT$1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of ScinoPharm Taiwan Ltd:

  • The MRQ is 9.3%. The company is operating less efficient.
  • The TTM is 13.2%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ9.3%TTM13.2%-3.9%
TTM13.2%YOY10.3%+2.9%
TTM13.2%5Y11.6%+1.6%
5Y11.6%10Y14.4%-2.8%
4.3.2.2. Operating Ratio

Measures how efficient Scinopharm is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.91 means that the operating costs are NT$0.91 for each NT$1 in net sales.

Let's take a look of the Operating Ratio trends of ScinoPharm Taiwan Ltd:

  • The MRQ is 0.907. The company is less efficient in keeping operating costs low.
  • The TTM is 0.881. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.907TTM0.881+0.026
TTM0.881YOY0.914-0.034
TTM0.8815Y0.895-0.014
5Y0.89510Y0.865+0.030
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of ScinoPharm Taiwan Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Scinopharm is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 6.86 means the company has NT$6.86 in assets for each NT$1 in short-term debts.

Let's take a look of the Current Ratio trends of ScinoPharm Taiwan Ltd:

  • The MRQ is 6.862. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.194. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.862TTM8.194-1.332
TTM8.194YOY7.540+0.654
TTM8.1945Y7.975+0.219
5Y7.97510Y5.817+2.158
4.4.3.2. Quick Ratio

Measures if Scinopharm is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Scinopharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 4.83 means the company can pay off NT$4.83 for each NT$1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of ScinoPharm Taiwan Ltd:

  • The MRQ is 4.834. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.922. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.834TTM5.922-1.088
TTM5.922YOY5.838+0.084
TTM5.9225Y6.073-0.151
5Y6.07310Y4.282+1.791
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of ScinoPharm Taiwan Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Scinopharm assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Scinopharm to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.14 means that Scinopharm assets are financed with 13.5% credit (debt) and the remaining percentage (100% - 13.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of ScinoPharm Taiwan Ltd:

  • The MRQ is 0.135. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.122. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.135TTM0.122+0.014
TTM0.122YOY0.127-0.005
TTM0.1225Y0.122-0.001
5Y0.12210Y0.158-0.035
4.5.4.2. Debt to Equity Ratio

Measures if Scinopharm is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Scinopharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 15.7% means that company has NT$0.16 debt for each NT$1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of ScinoPharm Taiwan Ltd:

  • The MRQ is 0.157. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.139. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.157TTM0.139+0.018
TTM0.139YOY0.146-0.007
TTM0.1395Y0.139-0.001
5Y0.13910Y0.189-0.050
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every NT$1 in earnings Scinopharm generates.

  • Above 15 is considered overpriced but always compare Scinopharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 76.65 means the investor is paying NT$76.65 for every NT$1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of ScinoPharm Taiwan Ltd:

  • The EOD is 63.961. Based on the earnings, the company is expensive. -2
  • The MRQ is 76.648. Based on the earnings, the company is expensive. -2
  • The TTM is 81.544. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD63.961MRQ76.648-12.687
MRQ76.648TTM81.544-4.896
TTM81.544YOY81.331+0.213
TTM81.5445Y140.849-59.305
5Y140.84910Y168.441-27.592
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of ScinoPharm Taiwan Ltd:

  • The EOD is -564.075. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -675.958. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -214.408. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-564.075MRQ-675.958+111.883
MRQ-675.958TTM-214.408-461.550
TTM-214.408YOY61.597-276.005
TTM-214.4085Y34.371-248.779
5Y34.37110Y35.768-1.396
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Scinopharm is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 2.21 means the investor is paying NT$2.21 for each NT$1 in book value.

Let's take a look of the Price to Book Ratio trends of ScinoPharm Taiwan Ltd:

  • The EOD is 1.847. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.213. Based on the equity, the company is underpriced. +1
  • The TTM is 2.111. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.847MRQ2.213-0.366
MRQ2.213TTM2.111+0.103
TTM2.111YOY2.030+0.080
TTM2.1115Y2.090+0.021
5Y2.09010Y2.724-0.634
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in TWD. All numbers in thousands.

Summary
Total Assets11,995,608
Total Liabilities1,623,644
Total Stockholder Equity10,371,964
 As reported
Total Liabilities 1,623,644
Total Stockholder Equity+ 10,371,964
Total Assets = 11,995,608

Assets

Total Assets11,995,608
Total Current Assets6,672,785
Long-term Assets5,322,823
Total Current Assets
Cash And Cash Equivalents 4,206,801
Net Receivables 494,161
Inventory 1,815,076
Other Current Assets 156,747
Total Current Assets  (as reported)6,672,785
Total Current Assets  (calculated)6,672,785
+/- 0
Long-term Assets
Property Plant Equipment 4,589,252
Long-term Assets Other 2,361
Long-term Assets  (as reported)5,322,823
Long-term Assets  (calculated)4,591,613
+/- 731,210

Liabilities & Shareholders' Equity

Total Current Liabilities972,478
Long-term Liabilities651,166
Total Stockholder Equity10,371,964
Total Current Liabilities
Short-term Debt 29,526
Short Long Term Debt 10,899
Accounts payable 147,324
Other Current Liabilities 650,852
Total Current Liabilities  (as reported)972,478
Total Current Liabilities  (calculated)838,601
+/- 133,877
Long-term Liabilities
Capital Lease Obligations 643,548
Long-term Liabilities Other 893
Long-term Liabilities  (as reported)651,166
Long-term Liabilities  (calculated)644,441
+/- 6,725
Total Stockholder Equity
Common Stock7,907,392
Retained Earnings 356,215
Accumulated Other Comprehensive Income 842,705
Other Stockholders Equity 1,265,652
Total Stockholder Equity (as reported)10,371,964
Total Stockholder Equity (calculated)10,371,964
+/-0
Other
Capital Stock7,907,392
Cash and Short Term Investments 4,206,801
Common Stock Shares Outstanding 791,663
Current Deferred Revenue144,776
Liabilities and Stockholders Equity 11,995,608
Net Debt -3,552,354
Net Invested Capital 10,382,863
Net Working Capital 5,700,307
Property Plant and Equipment Gross 4,589,252
Short Long Term Debt Total 654,447



6.2. Balance Sheets Structured

Currency in TWD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-30
> Total Assets 
0
7,298,230
0
7,624,359
8,965,185
9,480,188
9,688,747
9,823,137
9,545,439
10,312,981
11,037,118
11,702,472
11,120,130
11,484,228
12,029,244
11,794,738
11,241,349
11,371,820
11,571,094
11,874,422
11,994,572
12,221,595
12,491,045
12,545,331
12,508,519
12,783,000
12,853,058
12,880,678
12,869,761
12,701,389
13,155,454
13,255,497
12,807,388
12,563,328
13,729,538
13,600,763
11,722,021
11,674,564
11,652,140
12,108,379
12,000,197
11,846,763
12,178,179
12,078,396
11,448,685
11,691,176
11,940,627
12,035,540
11,739,328
11,911,176
11,971,530
11,889,505
11,567,094
11,721,586
11,974,808
11,995,608
11,995,60811,974,80811,721,58611,567,09411,889,50511,971,53011,911,17611,739,32812,035,54011,940,62711,691,17611,448,68512,078,39612,178,17911,846,76312,000,19712,108,37911,652,14011,674,56411,722,02113,600,76313,729,53812,563,32812,807,38813,255,49713,155,45412,701,38912,869,76112,880,67812,853,05812,783,00012,508,51912,545,33112,491,04512,221,59511,994,57211,874,42211,571,09411,371,82011,241,34911,794,73812,029,24411,484,22811,120,13011,702,47211,037,11810,312,9819,545,4399,823,1379,688,7479,480,1888,965,1857,624,35907,298,2300
   > Total Current Assets 
0
4,078,466
0
4,277,907
5,447,281
5,866,878
6,038,850
5,921,641
5,498,416
6,058,509
6,524,831
6,925,278
6,114,919
6,143,428
6,406,509
5,997,057
5,271,881
5,249,555
5,443,736
5,685,028
5,715,866
6,032,910
6,146,745
6,198,468
6,261,611
6,585,375
6,656,473
6,602,915
6,609,480
6,467,127
6,743,333
6,850,993
6,520,050
6,506,167
6,624,810
6,676,744
5,305,535
5,406,584
5,568,670
5,870,070
6,036,917
5,916,137
6,106,784
6,191,345
5,647,157
5,966,529
6,122,505
6,262,789
6,089,149
6,320,341
6,450,463
6,447,760
6,161,527
6,380,608
6,607,527
6,672,785
6,672,7856,607,5276,380,6086,161,5276,447,7606,450,4636,320,3416,089,1496,262,7896,122,5055,966,5295,647,1576,191,3456,106,7845,916,1376,036,9175,870,0705,568,6705,406,5845,305,5356,676,7446,624,8106,506,1676,520,0506,850,9936,743,3336,467,1276,609,4806,602,9156,656,4736,585,3756,261,6116,198,4686,146,7456,032,9105,715,8665,685,0285,443,7365,249,5555,271,8815,997,0576,406,5096,143,4286,114,9196,925,2786,524,8316,058,5095,498,4165,921,6416,038,8505,866,8785,447,2814,277,90704,078,4660
       Cash And Cash Equivalents 
0
1,908,362
0
2,008,622
3,194,711
3,293,681
3,236,191
2,972,185
2,302,974
3,035,012
3,411,045
3,378,997
2,734,079
2,289,428
2,792,770
2,184,375
1,303,052
1,927,603
2,007,522
2,409,774
1,846,093
2,335,697
2,559,704
2,964,318
3,137,413
3,707,151
3,715,269
3,720,965
3,950,339
3,910,791
3,938,230
4,017,339
3,978,337
4,203,338
4,532,835
4,533,737
3,143,457
3,304,978
3,691,131
3,803,140
3,759,293
4,054,948
4,040,196
4,104,077
3,732,474
4,080,921
4,166,169
4,345,460
4,245,705
4,294,709
4,433,725
4,241,784
3,994,616
3,941,524
4,225,826
4,206,801
4,206,8014,225,8263,941,5243,994,6164,241,7844,433,7254,294,7094,245,7054,345,4604,166,1694,080,9213,732,4744,104,0774,040,1964,054,9483,759,2933,803,1403,691,1313,304,9783,143,4574,533,7374,532,8354,203,3383,978,3374,017,3393,938,2303,910,7913,950,3393,720,9653,715,2693,707,1513,137,4132,964,3182,559,7042,335,6971,846,0932,409,7742,007,5221,927,6031,303,0522,184,3752,792,7702,289,4282,734,0793,378,9973,411,0453,035,0122,302,9742,972,1853,236,1913,293,6813,194,7112,008,62201,908,3620
       Short-term Investments 
0
10,897
0
20,399
19,927
21,993
20,143
4,375
3,254
473
0
0
17,136
15,552
15,552
1,796
-370,116
-379,356
1,846
-330,581
531,575
284,216
427,108
123,113
49,123
416,998
3,201
442,534
442,723
443,262
275,782
281,305
334,022
179,024
183,668
182,531
260,537
175,140
316,520
405
258,418
34,311
132,281
90,213
90,501
50,711
50,911
50,634
51,127
51,132
51,070
0
0
8,304
0
0
008,3040051,07051,13251,12750,63450,91150,71190,50190,213132,28134,311258,418405316,520175,140260,537182,531183,668179,024334,022281,305275,782443,262442,723442,5343,201416,99849,123123,113427,108284,216531,575-330,5811,846-379,356-370,1161,79615,55215,55217,136004733,2544,37520,14321,99319,92720,399010,8970
       Net Receivables 
0
0
0
703,256
684,255
0
798,867
813,207
1,025,799
841,334
599,227
870,455
689,279
970,871
629,660
792,667
865,939
523,017
653,049
568,524
648,279
867,231
645,287
677,566
614,015
638,405
635,495
726,413
470,231
567,318
589,093
709,231
534,211
558,950
412,130
434,024
439,183
590,336
397,772
553,999
467,657
386,508
397,206
426,534
338,368
393,043
490,818
457,299
361,864
653,545
430,467
579,515
382,940
813,451
559,794
494,161
494,161559,794813,451382,940579,515430,467653,545361,864457,299490,818393,043338,368426,534397,206386,508467,657553,999397,772590,336439,183434,024412,130558,950534,211709,231589,093567,318470,231726,413635,495638,405614,015677,566645,287867,231648,279568,524653,049523,017865,939792,667629,660970,871689,279870,455599,227841,3341,025,799813,207798,8670684,255703,256000
       Other Current Assets 
0
914,849
0
845,263
829,291
1,085,742
980,945
923,349
1,229,859
1,152,749
887,960
1,258,417
1,004,907
1,326,130
961,190
1,135,317
1,300,324
872,656
1,031,922
959,848
1,049,581
1,243,789
992,494
1,049,210
1,057,134
1,048,514
996,789
1,080,068
829,204
881,248
912,765
1,035,793
772,673
760,008
654,294
666,473
663,738
802,134
601,418
767,076
668,807
581,008
511,584
548,380
451,004
489,894
605,999
600,392
488,693
785,784
131,671
133,832
141,435
105,794
154,587
156,747
156,747154,587105,794141,435133,832131,671785,784488,693600,392605,999489,894451,004548,380511,584581,008668,807767,076601,418802,134663,738666,473654,294760,008772,6731,035,793912,765881,248829,2041,080,068996,7891,048,5141,057,1341,049,210992,4941,243,7891,049,581959,8481,031,922872,6561,300,3241,135,317961,1901,326,1301,004,9071,258,417887,9601,152,7491,229,859923,349980,9451,085,742829,291845,2630914,8490
   > Long-term Assets 
0
3,219,764
0
3,346,452
3,517,904
3,613,310
3,649,897
3,901,496
4,047,023
4,254,472
4,512,287
4,777,194
5,005,211
5,340,800
5,622,735
5,797,681
5,969,468
6,122,265
6,127,358
6,189,394
6,278,706
6,188,685
6,344,300
6,346,863
6,246,908
6,197,625
6,196,585
6,277,763
6,260,281
6,234,262
6,412,121
6,404,504
6,287,338
6,057,161
7,104,728
6,924,019
6,416,486
6,267,980
6,083,470
6,238,309
5,963,280
5,930,626
6,071,395
5,887,051
5,801,528
5,724,647
5,818,122
5,772,751
5,650,179
5,590,835
5,521,067
5,441,745
5,405,567
5,340,978
5,367,281
5,322,823
5,322,8235,367,2815,340,9785,405,5675,441,7455,521,0675,590,8355,650,1795,772,7515,818,1225,724,6475,801,5285,887,0516,071,3955,930,6265,963,2806,238,3096,083,4706,267,9806,416,4866,924,0197,104,7286,057,1616,287,3386,404,5046,412,1216,234,2626,260,2816,277,7636,196,5856,197,6256,246,9086,346,8636,344,3006,188,6856,278,7066,189,3946,127,3586,122,2655,969,4685,797,6815,622,7355,340,8005,005,2114,777,1944,512,2874,254,4724,047,0233,901,4963,649,8973,613,3103,517,9043,346,45203,219,7640
       Property Plant Equipment 
0
2,822,336
0
2,954,807
3,109,916
3,237,082
3,298,809
3,482,235
3,615,371
3,796,763
3,819,674
3,897,211
4,019,624
4,213,982
4,433,590
4,658,019
4,884,454
5,065,025
5,109,213
5,142,475
5,142,912
5,170,714
5,361,262
5,354,715
5,247,836
5,208,898
5,154,883
5,136,091
5,122,070
5,088,713
5,041,202
4,957,074
4,840,349
4,758,846
5,678,761
5,563,508
5,178,625
5,106,947
5,057,622
4,886,976
4,840,905
4,840,632
4,789,984
4,889,428
4,878,002
4,883,295
4,974,789
4,881,430
4,808,884
4,797,341
4,750,271
4,679,064
4,658,060
4,577,590
4,626,793
4,589,252
4,589,2524,626,7934,577,5904,658,0604,679,0644,750,2714,797,3414,808,8844,881,4304,974,7894,883,2954,878,0024,889,4284,789,9844,840,6324,840,9054,886,9765,057,6225,106,9475,178,6255,563,5085,678,7614,758,8464,840,3494,957,0745,041,2025,088,7135,122,0705,136,0915,154,8835,208,8985,247,8365,354,7155,361,2625,170,7145,142,9125,142,4755,109,2135,065,0254,884,4544,658,0194,433,5904,213,9824,019,6243,897,2113,819,6743,796,7633,615,3713,482,2353,298,8093,237,0823,109,9162,954,80702,822,3360
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
-93,404
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000-93,40400000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
364,089
364,089
391,097
391,097
391,097
539,572
605,853
611,434
468,117
646,225
589,354
491,876
444,480
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000444,480491,876589,354646,225468,117611,434605,853539,572391,097391,097391,097364,089364,0890000000000000000000000000
       Intangible Assets 
0
60,441
0
71,543
76,511
114,447
110,491
115,468
113,092
107,539
22,683
118,911
23,612
28,709
26,430
24,032
22,419
23,554
20,684
17,590
20,255
22,918
21,893
20,557
23,269
24,078
21,681
22,606
22,795
23,334
21,812
20,570
17,611
16,753
20,699
18,626
15,538
14,068
12,808
10,322
8,072
8,900
9,231
7,369
6,544
8,793
10,466
11,912
10,684
9,953
8,983
10,374
12,296
19,152
19,188
0
019,18819,15212,29610,3748,9839,95310,68411,91210,4668,7936,5447,3699,2318,9008,07210,32212,80814,06815,53818,62620,69916,75317,61120,57021,81223,33422,79522,60621,68124,07823,26920,55721,89322,91820,25517,59020,68423,55422,41924,03226,43028,70923,612118,91122,683107,539113,092115,468110,491114,44776,51171,543060,4410
       Other Assets 
0
0
0
404,127
418,490
0
359,188
426,835
437,554
464,154
692,613
879,983
985,587
1,126,818
1,189,145
1,139,662
1,085,014
1,057,240
1,018,145
1,046,919
1,135,794
1,017,971
983,038
992,148
999,072
988,727
1,041,702
1,141,672
1,138,211
1,145,549
1,370,919
821,007
817,944
813,445
759,043
752,531
730,447
731,755
738,598
768,269
780,766
772,979
792,242
806,522
834,420
882,044
923,133
885,715
912,195
970,396
0
1,032,323
0
0
0
0
00001,032,3230970,396912,195885,715923,133882,044834,420806,522792,242772,979780,766768,269738,598731,755730,447752,531759,043813,445817,944821,0071,370,9191,145,5491,138,2111,141,6721,041,702988,727999,072992,148983,0381,017,9711,135,7941,046,9191,018,1451,057,2401,085,0141,139,6621,189,1451,126,818985,587879,983692,613464,154437,554426,835359,1880418,490404,127000
> Total Liabilities 
0
620,972
0
607,440
677,702
870,908
877,486
1,457,305
883,408
1,217,506
1,575,695
2,593,000
1,772,178
1,840,974
2,221,702
2,635,129
1,916,105
1,991,549
2,094,562
2,424,188
2,294,058
2,364,602
2,463,954
2,587,552
2,413,984
2,555,207
2,494,818
2,649,233
2,518,468
2,284,164
2,438,202
2,725,371
2,215,968
2,024,296
2,910,860
3,179,707
1,412,428
1,414,620
1,513,172
1,726,763
1,515,014
1,317,360
1,366,754
1,693,158
1,127,171
1,180,122
1,301,011
1,652,788
1,343,616
1,461,123
1,513,247
1,712,860
1,324,712
1,357,156
1,449,872
1,623,644
1,623,6441,449,8721,357,1561,324,7121,712,8601,513,2471,461,1231,343,6161,652,7881,301,0111,180,1221,127,1711,693,1581,366,7541,317,3601,515,0141,726,7631,513,1721,414,6201,412,4283,179,7072,910,8602,024,2962,215,9682,725,3712,438,2022,284,1642,518,4682,649,2332,494,8182,555,2072,413,9842,587,5522,463,9542,364,6022,294,0582,424,1882,094,5621,991,5491,916,1052,635,1292,221,7021,840,9741,772,1782,593,0001,575,6951,217,506883,4081,457,305877,486870,908677,702607,4400620,9720
   > Total Current Liabilities 
0
595,313
0
581,102
651,033
842,949
848,675
1,427,892
853,135
1,187,327
1,510,069
2,527,232
1,706,267
1,774,787
2,155,555
2,569,191
1,849,036
1,918,033
2,003,613
2,332,723
2,198,743
2,274,983
2,374,152
2,248,214
1,533,616
1,691,693
1,691,573
1,365,484
1,218,961
1,115,458
1,182,610
2,653,844
2,145,380
1,945,644
1,958,920
1,144,878
563,013
741,747
806,929
1,091,124
881,607
686,646
739,034
1,066,847
503,453
556,314
627,728
986,814
678,758
803,094
877,263
1,080,588
695,813
729,453
794,921
972,478
972,478794,921729,453695,8131,080,588877,263803,094678,758986,814627,728556,314503,4531,066,847739,034686,646881,6071,091,124806,929741,747563,0131,144,8781,958,9201,945,6442,145,3802,653,8441,182,6101,115,4581,218,9611,365,4841,691,5731,691,6931,533,6162,248,2142,374,1522,274,9832,198,7432,332,7232,003,6131,918,0331,849,0362,569,1912,155,5551,774,7871,706,2672,527,2321,510,0691,187,327853,1351,427,892848,675842,949651,033581,1020595,3130
       Short-term Debt 
0
3,088
0
598
240
83
51
68
48
264,721
392,826
755,369
743,598
690,865
1,070,931
1,006,684
1,124,664
1,278,629
1,396,282
1,489,865
1,687,274
1,703,301
1,736,372
1,490,469
973,164
1,015,826
1,006,860
603,606
662,089
595,410
559,811
1,781,306
1,665,912
1,412,941
1,412,061
307,262
108,085
251,367
249,237
50,384
116,846
27,167
60,005
58,385
17,994
17,337
34,670
41,935
66,898
96,727
108,206
99,811
77,738
50,872
39,912
29,526
29,52639,91250,87277,73899,811108,20696,72766,89841,93534,67017,33717,99458,38560,00527,167116,84650,384249,237251,367108,085307,2621,412,0611,412,9411,665,9121,781,306559,811595,410662,089603,6061,006,8601,015,826973,1641,490,4691,736,3721,703,3011,687,2741,489,8651,396,2821,278,6291,124,6641,006,6841,070,931690,865743,598755,369392,826264,7214868518324059803,0880
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,785,698
1,693,481
1,788,707
109,163
219,536
222,618
1,336,086
1,303,966
1,178,503
1,388,628
283,829
92,071
235,353
232,228
35,240
101,702
10,667
43,501
41,881
1,490
1,172
17,450
25,055
50,359
78,834
90,313
81,918
59,845
33,316
20,946
10,899
10,89920,94633,31659,84581,91890,31378,83450,35925,05517,4501,1721,49041,88143,50110,667101,70235,240232,228235,35392,071283,8291,388,6281,178,5031,303,9661,336,086222,618219,536109,1631,788,7071,693,4811,785,6980000000000000000000000000
       Accounts payable 
0
142,734
0
111,672
134,773
299,250
284,419
251,266
242,737
223,074
294,241
279,096
298,529
264,437
225,020
220,409
195,013
53,813
163,104
191,471
125,235
91,060
154,397
140,247
129,031
69,730
97,289
90,229
160,170
90,784
78,020
91,902
81,196
89,393
67,073
102,520
91,308
101,018
139,748
132,853
106,345
159,671
166,318
144,507
57,794
69,690
91,254
115,879
134,547
125,264
166,886
173,563
140,792
101,278
197,435
147,324
147,324197,435101,278140,792173,563166,886125,264134,547115,87991,25469,69057,794144,507166,318159,671106,345132,853139,748101,01891,308102,52067,07389,39381,19691,90278,02090,784160,17090,22997,28969,730129,031140,247154,39791,060125,235191,471163,10453,813195,013220,409225,020264,437298,529279,096294,241223,074242,737251,266284,419299,250134,773111,6720142,7340
       Other Current Liabilities 
0
22,077
0
19,952
19,704
19,804
420,833
1,082,327
523,485
521,993
3,992
77,830
121
671,750
667,421
1,240,094
109
557,853
388,354
567,655
57
380,613
342,093
516,256
369,495
495,226
429,003
592,736
373,027
379,013
458,577
698,858
355,952
377,936
383,193
696,712
363,620
389,361
398,616
227,923
143,550
431,839
424,210
819,989
375,974
398,722
448,554
737,402
392,166
513,351
497,632
670,212
386,666
466,336
447,717
650,852
650,852447,717466,336386,666670,212497,632513,351392,166737,402448,554398,722375,974819,989424,210431,839143,550227,923398,616389,361363,620696,712383,193377,936355,952698,858458,577379,013373,027592,736429,003495,226369,495516,256342,093380,61357567,655388,354557,8531091,240,094667,421671,75012177,8303,992521,993523,4851,082,327420,83319,80419,70419,952022,0770
   > Long-term Liabilities 
0
25,659
0
26,338
26,669
27,959
28,811
29,413
30,273
30,179
65,626
65,768
65,911
66,187
66,147
65,938
67,069
73,516
90,949
91,465
95,315
89,619
89,802
339,338
880,368
863,514
803,245
1,283,749
1,299,507
1,168,706
1,255,592
71,527
70,588
78,652
951,940
2,034,829
849,415
672,873
706,243
635,639
633,407
630,714
627,720
626,311
623,718
623,808
673,283
665,974
664,858
658,029
635,984
632,272
628,899
627,703
654,951
651,166
651,166654,951627,703628,899632,272635,984658,029664,858665,974673,283623,808623,718626,311627,720630,714633,407635,639706,243672,873849,4152,034,829951,94078,65270,58871,5271,255,5921,168,7061,299,5071,283,749803,245863,514880,368339,33889,80289,61995,31591,46590,94973,51667,06965,93866,14766,18765,91165,76865,62630,17930,27329,41328,81127,95926,66926,338025,6590
       Other Liabilities 
0
0
0
25,850
26,423
0
28,811
29,413
30,273
30,179
65,626
65,768
65,911
65,548
65,579
65,633
65,704
70,360
90,598
90,841
91,972
86,251
88,899
88,853
84,696
91,764
71,637
71,524
71,422
71,024
70,848
71,527
70,588
78,652
78,440
79,122
76,878
82,853
82,026
81,961
82,024
80,532
80,089
81,241
81,216
83,542
85,715
80,862
82,209
76,848
0
56,718
0
0
0
0
000056,718076,84882,20980,86285,71583,54281,21681,24180,08980,53282,02481,96182,02682,85376,87879,12278,44078,65270,58871,52770,84871,02471,42271,52471,63791,76484,69688,85388,89986,25191,97290,84190,59870,36065,70465,63365,57965,54865,91165,76865,62630,17930,27329,41328,811026,42325,850000
> Total Stockholder Equity
0
6,677,272
0
7,016,946
8,285,702
8,607,561
8,809,585
8,364,135
8,660,367
9,093,872
9,459,776
9,109,472
9,347,952
9,643,254
9,807,542
9,159,609
9,325,244
9,380,271
9,476,532
9,450,234
9,700,514
9,856,993
10,027,091
9,957,779
10,094,535
10,227,793
10,358,240
10,231,445
10,351,293
10,417,225
10,717,252
10,530,126
10,591,420
10,539,032
10,818,678
10,421,056
10,309,593
10,259,944
10,138,968
10,381,616
10,485,183
10,529,403
10,811,425
10,385,238
10,321,514
10,511,054
10,639,616
10,382,752
10,395,712
10,450,053
10,458,283
10,176,645
10,242,382
10,364,430
10,524,936
10,371,964
10,371,96410,524,93610,364,43010,242,38210,176,64510,458,28310,450,05310,395,71210,382,75210,639,61610,511,05410,321,51410,385,23810,811,42510,529,40310,485,18310,381,61610,138,96810,259,94410,309,59310,421,05610,818,67810,539,03210,591,42010,530,12610,717,25210,417,22510,351,29310,231,44510,358,24010,227,79310,094,5359,957,77910,027,0919,856,9939,700,5149,450,2349,476,5329,380,2719,325,2449,159,6099,807,5429,643,2549,347,9529,109,4729,459,7769,093,8728,660,3678,364,1358,809,5858,607,5618,285,7027,016,94606,677,2720
   Common Stock
0
6,100,000
0
6,100,000
6,310,000
6,310,000
6,310,000
6,499,300
6,499,300
6,499,300
6,499,300
6,759,272
6,759,272
6,759,272
6,759,272
7,029,643
7,029,643
7,029,643
7,029,643
7,310,829
7,310,829
7,310,829
7,310,829
7,603,262
7,603,262
7,603,262
7,603,262
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,392
7,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,907,3927,603,2627,603,2627,603,2627,603,2627,310,8297,310,8297,310,8297,310,8297,029,6437,029,6437,029,6437,029,6436,759,2726,759,2726,759,2726,759,2726,499,3006,499,3006,499,3006,499,3006,310,0006,310,0006,310,0006,100,00006,100,0000
   Retained Earnings Total Equity00000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
5,477
288,795
14,987
44,355
40,756
279,180
50,449
100,674
81,792
342,697
114,633
69,095
64,638
330,020
6,103
-3,454
-46,612
270,891
-23,951
-19,765
142,637
201,959
178,710
39,616
240,153
172,200
26,007
-67,826
-224,348
58,356
-51,065
-33,043
894,470
769,745
697,189
650,992
742,724
820,172
779,870
682,533
648,752
705,679
740,697
667,465
717,301
842,705
842,705717,301667,465740,697705,679648,752682,533779,870820,172742,724650,992697,189769,745894,470-33,043-51,06558,356-224,348-67,82626,007172,200240,15339,616178,710201,959142,637-19,765-23,951270,891-46,612-3,4546,103330,02064,63869,095114,633342,69781,792100,67450,449279,18040,75644,35514,987288,7955,4770000000000
   Capital Surplus 00000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
497,653
0
506,817
1,325,658
1,327,549
1,282,292
1,387,834
1,358,807
1,370,326
1,373,703
1,230,966
1,490,750
1,491,569
1,250,338
982,538
1,255,507
1,257,277
1,630,743
1,400,350
1,683,941
1,685,072
1,687,705
1,461,431
1,756,556
1,755,231
1,715,549
1,527,415
1,811,149
1,816,001
1,837,773
1,882,039
1,884,091
1,883,686
1,884,334
1,929,286
1,929,948
1,862,208
1,705,876
1,997,078
1,946,208
1,963,736
1,246,972
1,246,972
1,246,972
1,294,689
1,254,273
1,254,273
1,246,972
1,294,689
1,294,689
1,256,454
1,256,454
1,294,689
1,265,336
1,265,652
1,265,6521,265,3361,294,6891,256,4541,256,4541,294,6891,294,6891,246,9721,254,2731,254,2731,294,6891,246,9721,246,9721,246,9721,963,7361,946,2081,997,0781,705,8761,862,2081,929,9481,929,2861,884,3341,883,6861,884,0911,882,0391,837,7731,816,0011,811,1491,527,4151,715,5491,755,2311,756,5561,461,4311,687,7051,685,0721,683,9411,400,3501,630,7431,257,2771,255,507982,5381,250,3381,491,5691,490,7501,230,9661,373,7031,370,3261,358,8071,387,8341,282,2921,327,5491,325,658506,8170497,6530



6.3. Balance Sheets

Currency in TWD. All numbers in thousands.




6.4. Cash Flows

Currency in TWD. All numbers in thousands.




6.5. Income Statements

Currency in TWD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in TWD. All numbers in thousands.

Gross Profit (+$)
totalRevenue3,186,083
Cost of Revenue-1,970,094
Gross Profit1,215,9891,215,989
 
Operating Income (+$)
Gross Profit1,215,989
Operating Expense-901,565
Operating Income357,920314,424
 
Operating Expense (+$)
Research Development357,740
Selling General Administrative364,174
Selling And Marketing Expenses179,651
Operating Expense901,565901,565
 
Net Interest Income (+$)
Interest Income53,628
Interest Expense-9,147
Other Finance Cost-0
Net Interest Income44,481
 
Pretax Income (+$)
Operating Income357,920
Net Interest Income44,481
Other Non-Operating Income Expenses0
Income Before Tax (EBT)348,840367,000
EBIT - interestExpense = 348,773
348,840
296,203
Interest Expense9,147
Earnings Before Interest and Taxes (EBIT)357,920357,987
Earnings Before Interest and Taxes (EBITDA)819,087
 
After tax Income (+$)
Income Before Tax348,840
Tax Provision-61,784
Net Income From Continuing Ops287,056287,056
Net Income287,056
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses2,871,659
Total Other Income/Expenses Net-9,080-44,481
 

Technical Analysis of Scinopharm
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Scinopharm. The general trend of Scinopharm is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Scinopharm's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of ScinoPharm Taiwan Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 25.80 < 25.80 < 26.50.

The bearish price targets are: 23.60 > 23.55 > 23.50.

Tweet this
ScinoPharm Taiwan Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of ScinoPharm Taiwan Ltd. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

ScinoPharm Taiwan Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of ScinoPharm Taiwan Ltd.

ScinoPharm Taiwan Ltd Daily Moving Average Convergence/Divergence (MACD) ChartScinoPharm Taiwan Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of ScinoPharm Taiwan Ltd. The current adx is .

ScinoPharm Taiwan Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of ScinoPharm Taiwan Ltd.

ScinoPharm Taiwan Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of ScinoPharm Taiwan Ltd.

ScinoPharm Taiwan Ltd Daily Relative Strength Index (RSI) ChartScinoPharm Taiwan Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of ScinoPharm Taiwan Ltd.

ScinoPharm Taiwan Ltd Daily Stochastic Oscillator ChartScinoPharm Taiwan Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of ScinoPharm Taiwan Ltd.

ScinoPharm Taiwan Ltd Daily Commodity Channel Index (CCI) ChartScinoPharm Taiwan Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of ScinoPharm Taiwan Ltd.

ScinoPharm Taiwan Ltd Daily Chande Momentum Oscillator (CMO) ChartScinoPharm Taiwan Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of ScinoPharm Taiwan Ltd.

ScinoPharm Taiwan Ltd Daily Williams %R ChartScinoPharm Taiwan Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of ScinoPharm Taiwan Ltd.

ScinoPharm Taiwan Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of ScinoPharm Taiwan Ltd.

ScinoPharm Taiwan Ltd Daily Average True Range (ATR) ChartScinoPharm Taiwan Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of ScinoPharm Taiwan Ltd.

ScinoPharm Taiwan Ltd Daily On-Balance Volume (OBV) ChartScinoPharm Taiwan Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of ScinoPharm Taiwan Ltd.

ScinoPharm Taiwan Ltd Daily Money Flow Index (MFI) ChartScinoPharm Taiwan Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for ScinoPharm Taiwan Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-06-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-06-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-06-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-06-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-06-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-06-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-07-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-07-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-11BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-19STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-22RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-07-23MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-25MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-07-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-07RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-08MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-08-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-30WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-09-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-09-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-16STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

ScinoPharm Taiwan Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of ScinoPharm Taiwan Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose23.300
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Scinopharm with someone you think should read this too:
  • Are you bullish or bearish on Scinopharm? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Scinopharm? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about ScinoPharm Taiwan Ltd

I send you an email if I find something interesting about ScinoPharm Taiwan Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about ScinoPharm Taiwan Ltd.

Receive notifications about ScinoPharm Taiwan Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.